Glycoprotein (GP) IIb/IIIa are now being widely used in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). With the growing use of these medications, there is an increase in adverse events related to them being reported in the literature, including severe thrombocytopenia.